Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: R. E. Simpson who wrote (18)	12/12/1998 1:34:00 PM
From: James Reynolds	Read Replies (1) \| Respond to of 447

Volume has been very heavy lately. I do not believe there is any trial data due soon (the Pfizer cancer compound successfully completed Phase I and only recently entered Phase II) so I assume the recent sell-off is due to either tax loss selling, an institution deciding they do not want OSI in their portfolio come year end, or a forced seller. The recent announcement from Pfizer regarding the cancer programme with OSI was very positive (several exciting compounds moving toward the clinic etc) so unless there is some serious bad news around the corner the shares are looking very cheap again.